NHCNYSEServices-Skilled Nursing Care FacilitiesFiscal year ends December 31
NATIONAL HEALTHCARE CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$239.24−3.58 (-1.47%)
Close on Oct 19, 2026
- Market cap
- $3.80B
- P/E (TTM)
- 26.9
- Dividend yield
- 1.06%
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
8.5%+3.8 pts over 5 years
Net margin
7.9%+3.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +16.1% | +11.8% | +8.1% | – | |
| Operating income | +42.8% | +59.1% | +21.7% | +6.7% | |
| Net income | +17.7% | +74.9% | +23.4% | +8.5% | |
| EPS, diluted | +17.5% | +74.2% | +23.0% | +9.1% | |
| Free cash flow | +86.5% | – | -3.9% | +19.5% | |
| Dividend per share | +4.5% | +3.8% | +4.0% | +5.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 7.8% | 5.3% | 11.7% | |
| Return on assets | 4.7% | 3.2% | 7.9% | |
| Current ratio | 1.93 | 1.62 | 1.82 | |
| Debt to equity | 0.18 | – | 0.04 | |
| Net debt to EBITDA | 0.89× | – | -0.30× | |
| Interest coverage | 15.4× | 34.4× | 20.1× | |
| Capex to revenue | 6.8% | 2.1% | 2.4% | |
| Diluted shares | 15M | 15M | 16M |
Where the cash went
Fiscal 2021 to 2025, five years combined
National Healthcare generated $474.73M from operations and spent $380.86M on capital expenditure, dividends and share buybacks. 42% of that went back into the business.
Generated
$474.73M
Used
$380.86M
Capital expenditure$161.55M42%Dividends$177.86M47%Share buybacks$41.45M11%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin7.9%
×Asset turnover0.99×
×Equity multiplier1.49×
=Return on equity, FY202511.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 7.9% | 0.99× | 1.49× | 11.7% |
| FY2024 | 7.8% | 0.92× | 1.50× | 10.8% |
| FY2023 | 5.9% | 0.88× | 1.45× | 7.5% |
| FY2022 | 2.1% | 0.81× | 1.51× | 2.5% |
| FY2021 | 12.9% | 0.78× | 1.63× | 16.3% |
| FY2020 | 4.1% | 0.78× | 1.68× | 5.3% |
| FY2019 | 6.8% | 0.84× | 1.57× | 9.0% |
| FY2018 | 6.0% | 0.90× | 1.52× | 8.2% |
| FY2017 | 5.8% | 0.88× | 1.59× | 8.2% |
| FY2016 | 5.5% | 0.87× | 1.64× | 7.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$120.02M
- Cash generatingOperating cash flow above zero$185.08M
- Return on assets improvedROA up on the prior year7.8% → 7.9%
- Earnings backed by cashOperating cash flow above net income$185.08M vs $120.02M
- Less leverageLong-term debt to assets fell8.5% → 2.1%
- Better liquidityCurrent ratio rose1.81 → 1.82
- No dilutionShare count did not rise16M → 16M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose1.00 → 1.00